ADMA AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
ADMA Current Performance
0.61%
Adma biologics inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ADMA
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
HALO | Halozyme therapeutics, inc. | 5 | 5 | 5 | 2 | 1 | |
SGMT | Sagimet biosciences inc | - | 1 | 3 | 2 | 1 | |
ITOS | Iteos therapeutics inc | 1 | 3 | 4 | 1 | 1 | |
MNKD | Mannkind corporation | 3 | 5 | 3 | 3 | 1 | |
APGE | Apogee therapeutics inc | - | 3 | 2 | 3 | 1 |
- HALO Halozyme therapeutics, inc.Value 5Trend 5Swing Trading 5Whale Interest 2Dividend 1See more
ADMA Profile
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.